{"answer":{"query":"jardiance","resolved_as":"name","packages":6,"applications":["NDA204629"],"identity":{"application_numbers":["NDA204629"],"marketing_categories":["NDA"],"labelers":[{"text":"BOEHRINGER INGELHEIM PHARMACEUTICALS","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true}],"marketing_start":{"earliest":"2014-08-01","latest":"2014-08-01","packages_with_a_start_date":6}},"price":{"median_negotiated_over_nadac":0.607,"packages_compared":6,"packages_listed":6,"negotiated_price_ends":null,"rows":[{"ndc":"00597015230","name":{"text":"Jardiance 10mg Tablets 30s","untrusted":true},"class":"B","nadac_per_unit":11.18898,"negotiated_per_unit":6.793978,"ratio":0.607,"ful_per_unit":null},{"ndc":"00597015237","name":{"text":"Jardiance (3x10) Blister Cards","untrusted":true},"class":"B","nadac_per_unit":11.18898,"negotiated_per_unit":6.793978,"ratio":0.607,"ful_per_unit":null},{"ndc":"00597015290","name":{"text":"Jardiance 10mg Tablets 90s","untrusted":true},"class":"B","nadac_per_unit":11.18898,"negotiated_per_unit":6.793978,"ratio":0.607,"ful_per_unit":null},{"ndc":"00597015330","name":{"text":"Jardiance 25mg Tablets 30s","untrusted":true},"class":"B","nadac_per_unit":11.18957,"negotiated_per_unit":6.793978,"ratio":0.607,"ful_per_unit":null},{"ndc":"00597015337","name":{"text":"Jardiance (3x10) Blister Cards","untrusted":true},"class":"B","nadac_per_unit":11.18957,"negotiated_per_unit":6.793978,"ratio":0.607,"ful_per_unit":null},{"ndc":"00597015390","name":{"text":"Jardiance 25mg Tablets 90s","untrusted":true},"class":"B","nadac_per_unit":11.18957,"negotiated_per_unit":6.793978,"ratio":0.607,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":202.33,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA204629","date":"2034-12-11","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"9949998*PED","productNo":"001"},"latest_patent_expiry":"2034-12-11","latest_exclusivity_expiry":"2026-12-20","dated_barriers":56,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":15,"exclusivities_listed":3,"fact_id":"087565f9f59bd0fa3437ff79"}],"label_history":{"events_total":25,"non_cmc_events":22,"counts_by_class":{"LABELING":13,"EFFICACY":9},"cmc_events":3,"recent_non_cmc_events":[{"application":"NDA204629","submission_no":63,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-24","documents":[{"type":"Label","date":"2025-10-27","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204629s063lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-10-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/204629Orig1s063,206111Orig1s046,208658Orig1s034,206073Orig1s044,212614Orig1s029ltr.pdf","untrusted":true}}],"fact_id":"c666c02a738e36512d160741"},{"application":"NDA204629","submission_no":40,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-09-21","documents":[{"type":"Letter","date":"2023-09-22","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204629Orig1s040ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-09-25","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf","untrusted":true}}],"fact_id":"e55037540123705eb5c916c7"},{"application":"NDA204629","submission_no":41,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-09-12","documents":[{"type":"Letter","date":"2023-09-13","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204629Orig1s041ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-09-13","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s041lbl.pdf","untrusted":true}}],"fact_id":"709b094a482c0c288c0fb5f5"},{"application":"NDA204629","submission_no":42,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-06-20","documents":[{"type":"Letter","date":"2023-06-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204629Orig1s042ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-06-22","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s042lbl.pdf","untrusted":true}}],"fact_id":"e965f5f33f95141e482cc209"},{"application":"NDA204629","submission_no":39,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-10-13","documents":[{"type":"Letter","date":"2022-10-14","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/204629Orig1s039,206073Orig1s033,206111Orig1s036,208658Orig1s023ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-10-17","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s039lbl.pdf","untrusted":true}}],"fact_id":"046552678675c8ba0359aa19"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":2,"te_code_counts":{"AB":2},"marketing_status_counts":{"Prescription":2},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA204629","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"JARDIANCE","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"10MG","untrusted":true}},{"application":"NDA204629","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"JARDIANCE","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"25MG","untrusted":true}}]},"recalls":{"recalls_total":2,"counts_by_class":{"Class II":2},"packages_of_these_applications":6,"most_recent":[{"recall_number":"D-0185-2024","classification":"Class II","status":"Terminated","report_date":"2024-01-03","recall_initiated":"2022-01-26","recalling_firm":{"text":"CARDINAL HEALTHCARE","untrusted":true},"reason":{"text":"CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.","untrusted":true},"packages_named":6,"fact_id":"d3211ed30dc074c4614fcb5e"},{"recall_number":"D-0468-2023","classification":"Class II","status":"Terminated","report_date":"2023-03-29","recall_initiated":"2023-03-09","recalling_firm":{"text":"Boehringer Ingelheim Pharmaceuticals, Inc.","untrusted":true},"reason":{"text":"Labeling: Label Mix-up","untrusted":true},"packages_named":6,"fact_id":"de7761f87cb65791ee55fd21"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"EMPAGLIFLOZIN","untrusted":true},"recruiting_interventional_count":94,"not_yet_recruiting_count":29,"by_phase":{"PHASE1/PHASE2":4,"PHASE3":18,"PHASE1":7,"PHASE4":29,"PHASE2":18,"EARLY_PHASE1":8,"NA":6,"PHASE2/PHASE3":4},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT03424005","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2018-03-30","link":{"text":"https://clinicaltrials.gov/study/NCT03424005","untrusted":true}},{"nct_id":"NCT05972564","title":{"text":"The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Vanderbilt University Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2023-09-06","link":{"text":"https://clinicaltrials.gov/study/NCT05972564","untrusted":true}},{"nct_id":"NCT07038356","title":{"text":"Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Christian Schulze","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2025-12-08","link":{"text":"https://clinicaltrials.gov/study/NCT07038356","untrusted":true}},{"nct_id":"NCT07845630","title":{"text":"A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Boehringer Ingelheim","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-29","start_date":"2026-10-14","link":{"text":"https://clinicaltrials.gov/study/NCT07845630","untrusted":true}},{"nct_id":"NCT06249932","title":{"text":"Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"National Taiwan University Hospital","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-28","start_date":"2024-03-13","link":{"text":"https://clinicaltrials.gov/study/NCT06249932","untrusted":true}}],"fact_id":"ab0e426b6d1a73f39080ec45"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Boehringer Ingelheim Cares Foundation","untrusted":true},"type":"manufacturer","url":"https://www.boehringer-ingelheim.com/us/boehringer-ingelheim-cares-foundation","status":{"state":"limited","effective":"2026-10-15","applies_to":null,"detail":{"text":"No new patient enrollments for individuals with Medicare Part D or Medicare Advantage prescription drug coverage for Boehringer Ingelheim primary care products (Combivent Respimat, Glyxambi, Jardiance, Jentadueto, Jentadueto XR, Spiriva Respimat, Stiolto Respimat, Synjardy, Synjardy XR, Tradjenta, Trijardy XR). Part D patients actively enrolled as of 2026-10-15 continue through their current enrollment period and may be eligible in 2027 only after annual re-enrollment. Product removals: Cyltezo 2026-07-15; OFEV 2026-09-11 (active patients continue through the end of their enrollment or 2027-12-31); no new enrollments for Aptivus, Atrovent and Striverdi from 2026-10-15.","untrusted":true},"read_on":"2026-11-06T12:00:00.000Z","source_url":"https://www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/pdf/pap-important-updates","proof_state":"eyes_checked"},"needs_status_check":true,"has_offer":false},{"name":{"text":"Jardiance Savings Card (BI/Lilly)","untrusted":true},"type":"manufacturer","url":"https://patient.boehringer-ingelheim.com/us/products/jardiance/savings/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Empagliflozin","untrusted":true},"brand":{"text":"Jardiance","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":2376166292.5,"claims":2677192,"beneficiaries":594859,"average_spending_per_claim_usd":887.55916365,"fact_id":"d34e21ece5f0d3433a7c5bfc"},{"year":2021,"gross_spending_usd":3735773560.2,"claims":3824726,"beneficiaries":884516,"average_spending_per_claim_usd":976.74279418,"fact_id":"6d81a1439ec0eae1ba14937d"},{"year":2022,"gross_spending_usd":5851720782,"claims":5653254,"beneficiaries":1321067,"average_spending_per_claim_usd":1035.1066451,"fact_id":"593dc293d747de3a2ac942f3"},{"year":2023,"gross_spending_usd":8839935063.3,"claims":8153238,"beneficiaries":1882768,"average_spending_per_claim_usd":1084.2238462,"fact_id":"e6cfa131bdb97204fc12a828"},{"year":2024,"gross_spending_usd":11435997421,"claims":11368280,"beneficiaries":2543331,"average_spending_per_claim_usd":1005.9566989,"fact_id":"4d9bbffe760147065d565969"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"empagliflozin","untrusted":true},"designation_count":1,"approved_count":0,"recent":[{"designated":"2026-11-02","use":{"text":"treatment of glycogen storage disease type 1b (GSD1b)","untrusted":true},"status":"Designated","sponsor":{"text":"Vitalis Scientia LLC","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"2bdcac1644e899b98d840283"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":4,"all_states_medicaid_reimbursed_usd":266541.1,"all_states_medicaid_paid_prescriptions":496,"top_states":[{"state":"OH","medicaid_paid_prescriptions":190,"medicaid_reimbursed_usd":140941.46,"total_reimbursed_usd":141406.39,"packages":2,"covers":"fee_for_service_only","fact_id":"c89d2f5b6fbb3ec9ec24337a"},{"state":"LA","medicaid_paid_prescriptions":91,"medicaid_reimbursed_usd":45570.36,"total_reimbursed_usd":46143.38,"packages":1,"covers":"all_record_types","fact_id":"6eff3e828971ac017b6e572c"},{"state":"MO","medicaid_paid_prescriptions":120,"medicaid_reimbursed_usd":42418.73,"total_reimbursed_usd":42973.04,"packages":1,"covers":"all_record_types","fact_id":"cd56792ebfc88a54bcedad1b"},{"state":"MN","medicaid_paid_prescriptions":95,"medicaid_reimbursed_usd":37610.55,"total_reimbursed_usd":37667.37,"packages":1,"covers":"fee_for_service_only","fact_id":"b9a972d05e348df8f15a70b7"}],"unlabelled_state_code_xx":null,"built_from_facts":5,"facts_fee_for_service_only":3,"older_year_facts_not_used":236,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"b7410c26913210a244bb57ba","field":"ndc.listing","entity":"ndc:00597015230"},{"fact_id":"33e4b2235ca378fbd48d4100","field":"ndc.listing","entity":"ndc:00597015237"},{"fact_id":"a54388fb0ec2430c5f28b2c7","field":"ndc.listing","entity":"ndc:00597015290"},{"fact_id":"a141e137c92905aa5da9ab6f","field":"ndc.nadac_price","entity":"ndc:00597015230"},{"fact_id":"2b46e76e778ef51fdbf762fa","field":"ndc.nadac_price","entity":"ndc:00597015237"},{"fact_id":"e13ee40393f5a812dbeb9635","field":"ndc.nadac_price","entity":"ndc:00597015290"},{"fact_id":"3ad876170ae3004c5bea758b","field":"ndc.mfp","entity":"ndc:00597015230"},{"fact_id":"247d8a1a706d3932af7ebb37","field":"ndc.mfp","entity":"ndc:00597015237"},{"fact_id":"34fa7eeda66289544119efd6","field":"ndc.mfp","entity":"ndc:00597015290"},{"fact_id":"087565f9f59bd0fa3437ff79","field":"drug.generic_entry_earliest","entity":"application:NDA204629"},{"fact_id":"8b82e32d14d3968b11aea466","field":"drug.patent","entity":"application:NDA204629"},{"fact_id":"8c69bb96550a1ac21bf5168f","field":"drug.exclusivity","entity":"application:NDA204629"},{"fact_id":"c666c02a738e36512d160741","field":"drug.label_event","entity":"application:NDA204629"},{"fact_id":"e55037540123705eb5c916c7","field":"drug.label_event","entity":"application:NDA204629"},{"fact_id":"709b094a482c0c288c0fb5f5","field":"drug.label_event","entity":"application:NDA204629"},{"fact_id":"e965f5f33f95141e482cc209","field":"drug.label_event","entity":"application:NDA204629"},{"fact_id":"046552678675c8ba0359aa19","field":"drug.label_event","entity":"application:NDA204629"},{"fact_id":"fdbb2d7a2be045b07f389025","field":"drug.te_code","entity":"application:NDA204629"},{"fact_id":"1c4ce759a741e2479a5ba20a","field":"drug.marketing_status","entity":"application:NDA204629"},{"fact_id":"797135354c34097a7e5b2d43","field":"drug.te_code","entity":"application:NDA204629"},{"fact_id":"346078c0ea0aa6c78c2997f3","field":"drug.marketing_status","entity":"application:NDA204629"},{"fact_id":"d3211ed30dc074c4614fcb5e","field":"ndc.recall","entity":"ndc:00597015290"},{"fact_id":"de7761f87cb65791ee55fd21","field":"ndc.recall","entity":"ndc:00597015330"},{"fact_id":"ab0e426b6d1a73f39080ec45","field":"drug.trial_access","entity":"drug:empagliflozin"},{"fact_id":"68df1ac006fe0604fce257f6","field":"program.status","entity":"program:boehringer-ingelheim-cares"},{"fact_id":"d34e21ece5f0d3433a7c5bfc","field":"drug.partd_spending","entity":"drug:empagliflozin|jardiance"},{"fact_id":"6d81a1439ec0eae1ba14937d","field":"drug.partd_spending","entity":"drug:empagliflozin|jardiance"},{"fact_id":"593dc293d747de3a2ac942f3","field":"drug.partd_spending","entity":"drug:empagliflozin|jardiance"},{"fact_id":"e6cfa131bdb97204fc12a828","field":"drug.partd_spending","entity":"drug:empagliflozin|jardiance"},{"fact_id":"4d9bbffe760147065d565969","field":"drug.partd_spending","entity":"drug:empagliflozin|jardiance"},{"fact_id":"2bdcac1644e899b98d840283","field":"drug.orphan_designation","entity":"drug:empagliflozin"},{"fact_id":"c89d2f5b6fbb3ec9ec24337a","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597015337:OH"},{"fact_id":"6eff3e828971ac017b6e572c","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597015237:LA"},{"fact_id":"cd56792ebfc88a54bcedad1b","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597015337:MO"},{"fact_id":"b9a972d05e348df8f15a70b7","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597015237:MN"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}